Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+
The race to develop anti-TIGIT drugs continues to heat up, as a major I/O player partners with a biotech once riddled with setbacks.
Bristol Myers Squibb is enlisting a preclinical program from Agenus to its pipeline, plunking down $200 million upfront for a bispecific antibody that targets both TIGIT and another undisclosed target. The Big Pharma will sweeten the pot with up to $1.36 billion in potential milestones, and Agenus will retain options to develop the candidate in combination with some of its other programs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,500+ biopharma pros reading Endpoints daily — and it's free.